# US 2025/0082646 A1 · Ovarian anti-aging pharmaceutical composition and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082646 A1
- Document ID: US20250082646A1
- Status: Published application
- Kind: A1
- Application number: 18/728,674
- Filed: 2023-01-27
- Published: 2025-03-13
- Earliest claimed: 2022-01-27
- Assignees: Mitoimmune Therapeutics Inc.
- Applicants: Mitoimmune Therapeutics Inc.
- Inventors: Soon Ha Kim; Jae Ho Lee; Yu Jin Kim
- Web page: https://patentgrep.com/patent/US20250082646A1

## CPC

- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relate to: an ovarian anti-aging pharmaceutical composition comprising, as an active ingredient, a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof; an ovarian anti-aging method comprising same; and a pharmaceutical composition for preventing or treating diseases related to ovarian aging or dysfunction, wherein the compound of chemical formula 1 may exhibit the effects of restoring ovarian function and inhibiting ovarian aging, and may be effectively used for preventing or treating diseases related to ovarian aging or dysfunction.

## Claims

### Claim 1

A method for anti-ovarian aging, the method comprising:
administering a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof into a subject in need thereof:
In this formula,
n is an integer from 1 to 3,
m is 0 or 1,
A is phenyl,
R1 is hydrogen or C1-C6 alkyl,
R2 is hydrogen, halogen, C1-C6 alkoxy, —C1-C6 alkylene-OH, —(CH2)pCO2R7, —NHR8, —N(H)S(O)2R7, or —NHC(O)R7, wherein p is an integer from 0 to 3, R7 is hydrogen or C1-C3 alkyl, and R8 is C1-C3 alkylpiperidinyl or C1-C3 alkylsulfonyl,
R3 is hydrogen, halogen, C1-C6 alkyl, phenyl, or —(CH2)p-heterocycle, in which the heterocycle is a 5- or 6-membered ring including 1 or 2 hetero atoms selected from S, N, and O atoms, wherein p is an integer from 0 to 3, provided that when m is 0, R3 is phenyl,
R4 is halogen, C1-C6 alkyl, —C1-C6 alkylene-OH, —O-phenyl, —(CH2)pCO2R7, —(CH2)p-heterocycle, in which the heterocycle is a 5- or 6-membered ring including 1 or 2 hetero atoms selected from S, N, and O atoms, or proline-N-carbonyl wherein p is an integer from 0 to 3, and R7 is the same as defined above,
R5 is hydrogen or C1-C6 alkyl,
R6 is C1-C6 alkyl, C3-C6 cycloalkyl, heterocycle, or —C1-C6 alkylene-heterocycle, in which the heterocycle is a 3- to 8-membered ring including 1 to 3 hetero atoms selected from S, N, and O atoms, and R6 may be substituted with C1-C6 alkylamine, —C1-C6 alkylene-OH, or C1-C6 alkylsulfonyl.

### Claim 2 (depends on 1)

The method of claim 1,
wherein R3 is hydrogen, halogen, phenyl, or —(CH2)p-heterocycle in which the heterocycle is morpholino or piperazinonyl, and p is an integer of 0 or 1, provided that when m is 0, R3 is phenyl,
R4 is halogen, C1-C3 alkyl, —C1-C3 alkylene-OH, —O-phenyl, —(CH2)pCO2-ethyl, —(CH2)p-heterocycle in which the heterocycle is thiomorpholino, morpholino, piperazinonyl, or pyrrolidinyl, or proline-N-carbonyl, wherein p is an integer of 0 or 1,
R5 is hydrogen or C1-C3 alkyl,
R6 is C1-C3 alkyl, C3-C6 cycloalkyl, heterocycle, or —C1-C3 alkylene-heterocycle, wherein the heterocycle is tetrahydro-2H-pyran, or piperidinyl, and when R6 is heterocycle or —C1-C3 alkylene-heterocycle, the heterocycle may be substituted with C1-C6 alkylamine, —C1-C6 alkylene-OH, or C1-C6 alkylsulfonyl.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound of Chemical Formula 1 is any one selected from the group consisting of the following compounds:
<1>5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-N-(tetrahydro-2H-pyran-4-yl)-1H-indol-7-amine; <2> ethyl 7-(cyclopentylamino)-2-phenyl-1H-indol-5-carboxylate; <3>(7-(cyclopentylamino)-2-phenyl-1H-indol-5-yl)methanol; <4>5-chloro-N,1-dimethyl-2-phenyl-N-(tetrahydro-2H-pyran-4-yl)-1H-indol-7-amine; <5>4-((7-(cyclopentylamino)-2-(3-fluorophenyl)-1H-indol-5-yl)methyl)piperazin-2-one; <6>4-((2-phenyl-7-(((tetrahydro-2H-pyran-4-yl)methyl)amino)-1H-indol-5-yl)methyl)thiomorpholine 1,1-dioxide; <7>5-chloro-N-(1-methylpiperidin-4-yl)-2-phenyl-1H-indol-7-amine; <8>5-phenoxy-2-phenyl-N-(tetrahydro-2H-pyran-4-yl)-1H-indol-7-amine; <9>5-chloro-3-(morpholinomethyl)-2-phenyl-N-(tetrahydro-2H-pyran-4-yl)-1H-indol-7-amine; <10>2-(4-((5-fluoro-2-phenyl-1H-indol-7-yl)amino)piperidin-1-yl)ethan-1-ol; <11> N-(4-(5-chloro-7-(cyclopentylamino)-1H-indol-2-yl)phenyl)methanesulfonamide; <12>5-chloro-3-phenyl-N-(tetrahydro-2H-pyran-4-yl)-1H-indol-7-amine; <13>4-((2-(3-fluorophenyl)-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indol-5-yl)methyl)thiomorpholine 1,1-dioxide; <14>5-chloro-N-cyclopentyl-2-(4-((1-methylpiperidin-4-yl)amino)phenyl)-1H-indol-7-amine; <15>4-((7-(isopentylamino)-2-(4-methoxyphenyl)-1H-indol-5-yl)methyl)thiomorpholine 1,1-dioxide; <16> N-(4-(7-(cyclopentylamino)-5-((1,1-dioxidothiomorpholino)methyl)-1H-indol-2-yl)phenyl)acetamide; <17>4-((3-bromo-2-phenyl-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indol-5-yl)methyl)thiomorpholine 1,1-dioxide; <18>4-((5-chloro-2-phenyl-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indol-3-yl)methyl)piperazin-2-one; <19>4-((7-(methyl(tetrahydro-2H-pyran-4-yl)amino)-2-phenyl-1H-indol-5-yl)methyl)thiomorpholine 1,1-dioxide; <20>5-methyl-N-(1-(methylsulfonyl)piperidin-4-yl)-2-phenyl-1H-indol-7-amine; <21> N-(4-(5-(1,1-dioxidothiomorpholino)-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indol-2-yl)phenyl)acetamide; <22>4-((7-((1-(methylsulfonyl)piperidin-4-yl)amino)-2-phenyl-1H-indol-5-yl)methyl)thiomorpholine 1,1-dioxide; <23> N1-(5-chloro-2-phenyl-1H-indol-7-yl)-N4-methylcyclohexane-1,4-diamine; <24> methyl 2-(3-(5-chloro-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indol-2-yl)phenyl)acetate; <25> (2-phenyl-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indol-5-carbonyl)-D-proline; <26> (3-(5-chloro-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indol-2-yl)phenyl)methanol; <27> N-cyclopentyl-2-phenyl-5-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-7-amine; <28> methyl 2-(4-(5-chloro-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indol-2-yl)phenyl)acetate; <29> methyl 4-(5-chloro-7-(cyclopentylamino)-1H-indol-2-yl)benzoate; <30>2-(4-(5-chloro-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indol-2-yl)phenyl)ethan-1-ol; <31>3-bromo-5-(morpholinomethyl)-2-phenyl-N-(tetrahydro-2H-pyran-4-yl)-1H-indol-7-amine; and <32>4-((3-phenyl-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indol-5-yl)methyl)thiomorpholine 1,1-dioxide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound of Chemical Formula 1 is a compound of Chemical Formula 2 below,

### Claim 5 (depends on 1)

The method of claim 1, wherein the anti-ovarian aging is restoring the function of aged ovaries.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anti-ovarian aging includes one or more selected from the group consisting of an increased number of ovarian follicles, an increased number of oocytes, and an increased rate of preimplantation embryo development.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound of Chemical Formula 1 increases the expression of one or more genes selected from the group consisting of longevity-related genes such as SOD2 and SIRT1; steroidogenesis-related genes such as Edn2, Tbxa2r, Oxtr, and Adra1d; primordial follicle factors such as Nanog, Oct3/4, and p63; and ovarian function factors such as Lhcgr, AMH, GDF9, BMP15, and Kitl in cells.

### Claim 8 (depends on 1)

A method for preventing or treating a disease related to the aging or dysfunction of ovaries, the method comprising:
administering a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof:
In this formula, R1to R6, A, n, and m are each the same as defined in claim 1.

### Claim 9 (depends on 8)

The method of claim 8, wherein the disease related to the aging or dysfunction of ovaries includes one or more selected from the group consisting of premature ovarian failure, sterility, infertility, miscarriages, ovarian cysts, ovarian teratomas, ovarian endometriomas, polycystic ovary syndrome, menopause, menopausal symptoms, ovarian cancer, and oophoritis.

### Claim 10

(canceled)
